About amcure

Our approach, which targets one specific co-receptor, CD44v6 thereby blocking several relevant oncological pathways (VEGF/VEGFR-2, HGF/c-Met and MSP/RON), provides a potential novel mechanism for the treatment of patients with advanced and solid tumors that have already begun to spread throughout the body.

AMC303, our most advanced development candidate, has entered clinical development and has demonstrated strong effects in in vivo proof-of-concept studies and a high efficacy against different types of epithelial cancers.

Established in 2012, amcure GmbH is a spin-off from the Karlsruhe Institute of Technology and is sponsored by a grant from the German Federal Ministry of Education and Research.